Dan Hashimshony

Dan Hashimshony serves as CEO at Epitomee Medical. Epitomee Medical operates in the medical devices sector with approximately 35.0 employees.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • Our database includes 201,468 c suite-level executives.

Outlook Microsoft Office 365 Linkedin Marketing Solutions Mobile Friendly WordPress.org Google Tag Manager reCAPTCHA Typekit AI

gi tract ingestible therapeutic device ingestible devices weight management epitomee capsule therapeutic medical devices medical devices medical device oral delivery drug delivery therapeutic devices biologics delivery ingestible medical device medical equipment manufacturing chronic disease treatment mechanosensory stimulation targeted therapies self-administered treatment fda cleared ce approved shapeshifting capsule appetite control gastric emptying natural bowel movement drug-free weight loss bioavailability enhancement muco-adhesive layer ph-sensitive polymers transient drug delivery scaffold technology oral delivery solutions sanitary swallowing nutrient absorption symptoms management chronic illness support clinical studies safety & efficacy innovative therapies health technology biodegradable device medical device development patient adherence solvent-mediated release collaborative partnerships scientific validation dietary interventions patient empowerment metabolic disorder solutions satiation signals gastrointestinal tract non-invasive solutions neutraceutical deployments pharmaceutical advancements real-world outcomes consumer healthcare therapeutic innovations personalized medicine healthcare partnerships medical technology advancement hospital & health care

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Dan Hashimshony in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Epitomee Medical.

Dan Hashimshony's Position in the MessageCEO Database

• •Dan Hashimshony is 1 of 1 verified executive contact we track at Epitomee Medical.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •22 verified contacts work at medical devices companies in the 35.0 employee range (same size as Epitomee Medical).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Dan Hashimshony directly?

Dan Hashimshony's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Epitomee Medical. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Dan Hashimshony work for?

Dan Hashimshony is CEO at Epitomee Medical, a company in the medical devices sector with 35.0 employees.

Can I pitch or sell to Dan Hashimshony?

As CEO at Epitomee Medical, Dan Hashimshony is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Dan Hashimshony directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Dan Hashimshony in?

Dan Hashimshony works in the medical devices industry as CEO at Epitomee Medical. MessageCEO provides verified contact information for executives across all major industries.

Is Dan Hashimshony's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Dan Hashimshony's profile is kept up-to-date with the latest available information.

Last updated: July 28, 2026